In terms of therapeutic outcomes, ICIs targeting PD-1, PD-L1, and CTLA-4 have demonstrated efficacy in achieving prolonged survival in patients with aggressive lymphomas, even post-bone marrow transplant [169]. This evidence concerns the gene CD274 and lymphoma.